Uncategorized

Regeneron’s Phase 3 skin cancer miss adds to mounting failures in LAG-3

Published

4 weeks ago

on

May 18, 2026

By

Temp User

Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class.

The announcement follows a spate of recent clinical setbacks for candidates targeting the LAG-3 …

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Endpoints News3 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season

Exit mobile version